<DOC>
	<DOCNO>NCT00423397</DOCNO>
	<brief_summary>RATIONALE : Gefitinib may stop growth tumor cell block enzymes need cell growth . PEG-interferon alfa-2a may interfere growth tumor cell slow growth skin cancer . Giving gefitinib together PEG-interferon alfa-2a may kill tumor cell . PURPOSE : This phase I/II trial study side effect best dose PEG-interferon alfa-2a give together gefitinib see well work treat patient unresectable metastatic skin cancer .</brief_summary>
	<brief_title>Gefitinib PEG-Interferon Alfa-2a Treating Patients With Unresectable Metastatic Skin Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine tolerability gefitinib PEG-interferon alfa-2a patient unresectable metastatic squamous cell carcinoma skin . - Determine response rate patient treat gefitinib 1 month . - Determine whether addition weekly PEG-interferon alfa-2a ongoing gefitinib improve response rate patient . - Determine whether PEG-interferon alfa-2a exacerbates rash patient treat gefitinib 1 month . OUTLINE : This phase I , pilot , dose de-escalation study PEG-interferon alfa-2a follow open-label , phase II study . - Phase I : Patients receive oral gefitinib alone daily 4 week . Beginning week 5 , patient also receive PEG-interferon alfa-2a subcutaneously weekly . Treatment continue absence disease progression unacceptable toxicity . Cohorts patient receive de-escalating dos PEG-interferon alfa-2a tolerable dose determine . - Phase II : Patients receive gefitinib PEG-interferon alfa-2a tolerable dose determine phase I . PROJECTED ACCRUAL : A total 16 patient accrue study .</detailed_description>
	<mesh_term>Skin Neoplasms</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm primary squamous cell carcinoma skin Metastatic and/or unresectable locally recurrent disease Measurable disease No curative treatment option ( include resection radiotherapy ) exist unacceptably morbid PATIENT CHARACTERISTICS : WHO performance status 02 Absolute neutrophil count &gt; 1,500/mm³ Platelet count &gt; 100,000/mm³ Bilirubin &lt; 1.5 time upper limit normal Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception HIV/AIDS allow Patients cancer diagnosis ( e.g. , chronic lymphocytic leukemia ) eligible provide disease control require active treatment No preexist medical problem laboratory abnormality ≥ grade 3 except renal allograft patient chronic , stable grade 34 renal insufficiency dialysis candidate Nontransplant patient degree renal insufficiency allow No serious medical psychiatric illness would preclude study compliance No evidence severe uncontrolled ( ≥ grade 3 ) systemic disease ( e.g. , unstable uncompensated respiratory , cardiac , hepatic disease ) PRIOR CONCURRENT THERAPY : Prior solid organ transplant allow Prior cytotoxic chemotherapy radiotherapy allow More 30 day since prior experimental cancer treatment No prior epidermal growth factor receptorinhibiting drug , include gefitinib , erlotinib hydrochloride , cetuximab No concurrent radiotherapy No concurrent cytotoxic chemotherapy drug intend control skin cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>squamous cell carcinoma skin</keyword>
	<keyword>recurrent skin cancer</keyword>
</DOC>